Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sqz Biotechnologies Company
(NY:
SQZ
)
N/A
UNCHANGED
Last Price
Updated: 5:00 PM EDT, Jul 3, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sqz Biotechnologies Company
< Previous
1
2
3
Next >
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
May 06, 2024
From
GENENTA SCIENCE SPA
Via
GlobeNewswire
SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split
June 15, 2023
From
SQZ Biotechnologies Company
Via
Business Wire
SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates
May 10, 2023
From
SQZ Biotechnologies Company
Via
Business Wire
SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial
March 22, 2023
From
SQZ Biotechnologies Company
Via
Business Wire
SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates
March 22, 2023
From
SQZ Biotechnologies Company
Via
Business Wire
NYSE:SQZ Investor Alert: Investigation over Potential Wrongdoing at SQZ Biotechnologies Company
↗
February 27, 2023
San Diego, CA -- (SBWIRE) -- 02/27/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at SQZ Biotechnologies Company.
Via
SBWire
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange
January 18, 2023
From
SQZ Biotechnologies
Via
Business Wire
NYSE:SQZ Investor Notice: Investigation over Possible Securities Laws Violations by SQZ Biotechnologies Company
↗
December 13, 2022
San Diego, CA -- (SBWIRE) -- 12/13/2022 -- SQZ Biotechnologies Company is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress
December 06, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer
November 30, 2022
From
SQZ Biotechnologies
Via
Business Wire
SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting
November 10, 2022
From
SQZ Biotechnologies
Via
Business Wire
SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates
November 09, 2022
From
SQZ Biotechnologies
Via
Business Wire
SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy
October 03, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies
September 12, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
SQZ Biotechnologies to Present at Upcoming Investor Conferences
September 07, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
SQZ Biotechnologies Announces Leadership Transition
September 06, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates
August 04, 2022
From
SQZ Biotechnologies
Via
Business Wire
SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation
July 12, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
July 11, 2022
From
SQZ Biotechnologies
Via
Business Wire
SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
June 21, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs
June 16, 2022
From
SQZ Biotechnologies Company
Via
Business Wire
SQZ Biotechnologies to Present at Jefferies Healthcare Conference
June 01, 2022
From
SQZ Biotechnologies
Via
Business Wire
SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer
May 31, 2022
From
SQZ Biotechnologies
Via
Business Wire
SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process
May 18, 2022
From
SQZ Biotechnologies
Via
Business Wire
SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates
May 10, 2022
From
SQZ Biotechnologies
Via
Business Wire
SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022
May 05, 2022
From
SQZ Biotechnologies
Via
Business Wire
SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research
May 05, 2022
From
SQZ Biotechnologies
Via
Business Wire
SQZ Biotechnologies to Present at Upcoming Investor Conferences
May 03, 2022
From
SQZ Biotechnologies
Via
Business Wire
SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors
April 27, 2022
From
SQZ Biotechnologies
Via
Business Wire
SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo
April 11, 2022
From
SQZ Biotechnologies
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
